ライフサイエンスコーパス: dry mouth

1 classified as "dry mouth" and 66 as "without dry mouth".

2 ion, itching, poor mobility, poor sleep, and dry mouth).

3 ary and lacrimal glands causing dry eyes and dry mouth.

4 immune disease characterized by dry eyes and dry mouth.

5 adverse events were nausea, somnolence, and dry mouth.

6 al pocket depth, self-rated oral health, and dry mouth.

7 iation to the head and neck can also lead to dry mouth.

8 , resulting in symptoms such as dry eyes and dry mouth.

9 ost common adverse effects were sedation and dry mouth.

10 s) and different care need, with and without dry mouth.

11 when patients had not only dry eye but also dry mouth.

12 bo groups were dyskinesia, constipation, and dry mouth.

13 verse effects on the salivary gland, such as dry mouth.

14 abdominal pain, constipation, dizziness, and dry mouth.

15 re insomnia, decreased appetite, nausea, and dry mouth.

16 uld improve sensitivity for the diagnosis of dry mouth.

17 s included sedation, change in appetite, and dry mouth.

18 targets of radiotherapy-induced irreversible dry mouth.

19 ith a 2- to 3-year history of stomatitis and dry mouth.

20 e) were as follows: swallowing, 0.5/0.7, and dry mouth, 0.4/1.3.

21 h 24 Gy vs six [2%] of 301 sites with 4 Gy), dry mouth (11 [4%] vs five [2%]), fatigue (seven [2%] vs

22 8% and 36.2%), somnolence (21.2% and 18.1%), dry mouth (12.8% and 8.0%), and increased appetite (10.9

23 worse); swallowing, 8/9 (higher worse); and dry mouth, 14/45 (higher worse).

24 group), lethargy (34 [14%] vs 32 [14%]), and dry mouth (24 [10%] vs 21 [9%]), and there were no treat

25 The most common adverse events were dry mouth (24 [2%], 67 [13%], and 207 [21%] in the group

26 placebo, including fatigue (30% vs. 14%) and dry mouth (25% vs. 12%) in the amitriptyline group and p

27 ring impairment (13.6%), and 2 patients with dry mouth (4.5%).

28 s were somnolence (21.4% and 20.6% vs 4.8%); dry mouth (4.8% and 7.1% vs 0.8%); hypotension (6.3% and

29 ded hyperphosphatemia (65%), asthenia (55%), dry mouth (45%), nail toxicity (35%), constipation (34%)

30 e anticholinergic group had a higher rate of dry mouth (46% vs. 31%, P=0.02) but lower rates of cathe

31 0-GBq arm, the 7.4-GBq arm and overall, were dry mouth (47.8%; 63.4%; 57.8%, respectively), fatigue (

32 recipients), somnolence (5.1% vs. 1.5%), and dry mouth (5.1% vs. 0.8%) were the most frequently repor

33 , with the most common being cough (64%) and dry mouth (53%).

34 ng symptoms were more frequent at 12 months: dry mouth (58% v 17%), difficulties tasting (32% v 8%),

35 attributed to LuPSMA were self-limiting G1-2 dry mouth (66%), transient G1-2 nausea (48%), G3-4 throm

36 ted to (177)Lu-PSMA were self-limiting G1-G2 dry mouth (66%), transient G1-G2 nausea (48%), G3-G4 thr

37 ed appetite (10.7%), nasopharyngitis (9.0%), dry mouth (7.3%), and anxiety (5.1%).

38 lty swallowing; 8 (57%), oral pain; 7 (50%), dry mouth; 7 (50%), weight loss; 6 (43%), skin burning;

39 nation of sicca complex (marked dry eyes and dry mouth), abnormal pupillary light response, upper gas

40 Xerostomia, the subjective sensation of 'dry mouth' affecting at least 1 in 10 adults, predominan

41 ), without differences in the development of dry mouth, altered taste, or salivary gland pain.

42 than those for fatigue, but were similar to dry mouth and considerably higher than use of systemic t

43 Adverse effects were generally mild (eg, dry mouth and cough).

44 salivation, dizziness, and sweating and less dry mouth and decreased appetite than those treated with

45 Dimebon was well tolerated: dry mouth and depressed mood or depression were the most

46 the salivary and lacrimal glands, leading to dry mouth and dry eyes.

47 ctive assessment of the specific symptoms of dry mouth and dry eyes.

48 Adverse events reported included dry mouth and dry nose with apraclonidine and punctate k

49 was significantly associated with increased dry mouth and dysphonia (10 trials [7395 patients]; 3.0%

50 abial and lacrimal--leading to complaints of dry mouth and eyes.

51 Dry mouth and falls were reported more frequently in the

52 Corresponding proportions for dry mouth and fatigue were 48% and 45%, respectively.

53 prototypical drug used to treat glaucoma and dry mouth and is classified as either a full or partial

54 ell-characterized patients with dry eyes and dry mouth and lip biopsies from the Sjogren's Internatio

55 g onabotulinumtoxinA was less likely to have dry mouth and more likely to have complete resolution of

56 ite signs of infection-including taste loss, dry mouth and mucosal lesions such as ulcerations, enant

57 Complaints of dry mouth and tachycardia were significantly more freque

58 There was no difference between "dry mouth" and "without dry mouth" regarding identificat

59 5 patients included, 119 were classified as "dry mouth" and 66 as "without dry mouth".

60 f exocrine tissues, resulting in xerostomia (dry mouth) and keratoconjunctivitis sicca (dry eyes).

61 fficient education on AEs (e.g., fatigue and dry mouth) and radiation safety principles is key to eff

62 y and lacrimal glands leading to xerostomia (dry mouth) and xerophthalmia (dry eyes).

63 onstipation, thirst, leg swelling, numbness, dry mouth, and balance problems.

64 useful for drug therapy of cystic fibrosis, dry mouth, and gastrointestinal hypomotility disorders,

65 In the HABC Study, tooth loss, dry mouth, and having 3 oral problems were associated wi

66 ed with tolvaptan included increased thirst, dry mouth, and increased urination.

67 h comprised tooth loss, periodontal disease, dry mouth, and self-rated oral health.

68 h cotherapy were unpleasant taste, headache, dry mouth, and somnolence.

69 tension, and symptoms such as palpitations, dry mouth, and sweating.

70 Somnolence, dizziness, dry mouth, and weight gain occurred significantly more o

71 and is characterized by severe, sudden-onset dry mouth; and autoimmune polyendocrinopathy-candidiasis

72 Headache; pain in the mouth, lips, or gums; dry mouth; and sinus infection, pain, or discharge were

73 In Mali, those who presented with dry mouth (aOR: 3.16; 95% CI: 1.02-9.73) were more likel

74 Current treatments for xerostomia/dry mouth are palliative and largely ineffective.

75 g approaches to treat cancer therapy-induced dry mouth are presented using radiation-induced salivary

76 reasing number of the population suffer from dry mouth as a result of taking prescription drugs, with

77 Many important drug classes cause dry mouth as a side effect, contributing substantially t

78 th problems (mouth sores, difficulty eating, dry mouth, bad breath, and/or jaw pain), teeth problems

79 by 33%, although all patients complained of dry mouth before treatment.

80 In patients with dry eyes and dry mouth but F = 0, increased expression of anti- CA6 w

81 UWMS mucin concentrations are not reduced in dry mouth but that the mucin structure (glycosylation) i

82 Tolvaptan caused increased thirst and dry mouth, but frequencies of major adverse events were

83 Cannabis users frequently report dry mouth, but the basis for this is still unknown.

84 oms and subjective measures of stiffness and dry mouth, but the increases in systolic blood pressure

85 The prevalence of dry-mouth complaint, the absence of saliva upon palpatio

86 significantly higher incidence of headache, dry mouth, constipation, insomnia, and dizziness.

87 methorphan-bupropion were dizziness, nausea, dry mouth, decreased appetite, and anxiety.

88 Gene therapy for dry mouth disorders has transitioned in recent years fro

89 only possible drug related AEs reported were dry mouth, dizziness and anxiety in one patient and hypo

90 8 incidences of adverse effects (eg, nausea, dry mouth, dizziness, anxiety), whereas the acupuncture

91 odifications included constipation, fatigue, dry mouth, dizziness, nausea, anorexia, arrhythmia, head

92 ng CBMs significantly increased incidence of dry mouth, dizziness/light-headedness, and somnolence/dr

93 Over 90% of patients with dry mouth (DMPs) consistently had unstimulated whole mou

94 as well as improving subjective symptoms of dry mouth, dry eyes, and overall dryness.

95 mozygous for the CA12(E143K) mutation have a dry mouth, dry tongue phenotype.

96 and lacrimal gland dysfunction resulting in dry mouth/dry eye syndrome, remains ill-defined.

97 ne-trospium group were constipation, nausea, dry mouth, dyspepsia, and vomiting.

98 and number of comorbidities, but subjective dry mouth had no impact.

99 Among oral symptoms, dry mouth had the highest incidence, followed by bad bre

100 fetamine was associated with higher rates of dry mouth, headache, and insomnia, and topiramate was as

101 timate (hazard ratio [HR] = 0.92; P = .004), dry mouth (HR = 5.1; P < .0001), alkaline phosphatase mo

102 ients but have adverse effects of nausea and dry mouth in 1% to 4% of patients.

103 n 22 of 79 patients (28%) vs 18 of 78 (23%), dry mouth in 8 of 79 (10%) vs 12 of 78 (15%), and urinar

104 erties between sufferers and nonsufferers of dry mouth in order to understand the relationship betwee

105 ere was a higher incidence of late-occurring dry mouth in patients who were given venlafaxine than in

106 P-A pathway, nausea in the D-P pathway, and dry mouth in the A-P pathway.

107 nstrated differing profiles, including worse dry mouth in the RT arm (P = .032) and worse pain in the

108 is to determine whether acupuncture relieves dry mouth in this population.

109 opathic mucosal mouth dryness (xerostomia or dry mouth) in subjects without systemic diseases.

110 Management of dry mouth includes mechanical salivary stimulants, oral

111 The subjective feeling of dry mouth increased (P = 0.001).

112 isks of tooth loss, periodontal pockets, and dry mouth increased from IMD quintiles 1 to 5 (least to

113 Significantly more weight gain and cases of dry mouth, increased appetite, and somnolence were repor

114 uently during treatment with olanzapine were dry mouth, increased appetite, and somnolence.

115 during olanzapine treatment were somnolence, dry mouth, increased appetite, weight gain, akathisia, a

116 tudinally, particularly with tooth loss, and dry mouth, independent of individual-level socioeconomic

117 Es) reported by 10% of LDX participants were dry mouth, insomnia, and headache.

118 The most common adverse events were dry mouth, insomnia, and urinary hesitancy.

119 In people with CD, xerostomia or dry mouth is a common complication.

120 Dry mouth is a primary symptom of Sjogren's syndrome and

121 Dry mouth is associated with an 11.5% (95% CI, 3.6% to 2

122 Dry mouth is associated with using more than 3 oral medi

123 According to our results, subjective dry mouth is not a risk factor for an impaired ability t

124 Xerostomia, or dry mouth, is a common side effect of head and neck radi

125 irl presented with ileus, urinary retention, dry mouth, lack of tears, fixed dilated pupils, and diff

126 Dry mouth may indicate periodontal bone loss in children

127 eir limited real-time desorption (7%) from a dry-mouth mimicking hydrophobic surface unlike the teste

128 ds, irrespective of topography of the tested dry mouth-mimicking tribological surfaces.

129 rior to baseline measures except for senses, dry mouth, muscular tension, and cognitive functioning,

130 cts of the drug (e.g., headache, somnolence, dry mouth, nausea, and dizziness).

131 acebo+ADT group) were dizziness, somnolence, dry mouth, nausea, diarrhea, and fatigue; 12.4% versus 0

132 oderate in severity; insomnia, constipation, dry mouth, nausea, dizziness, hot flush, headache, hyper

133 Common AEs included dizziness, dry mouth, nausea, fatigue, somnolence, euphoria, vomiti

134 city, pain, but increased risk of dizziness, dry mouth, nausea, somnolence (GRADE=moderate).

135 Dry mouth occurred in 135/227 participants (59.5%; 2/227

136 ar component of SS, but not with symptoms of dry mouth or dry eyes.

137 was three times more common among those with dry mouth (OR = 3.05; 95% CI = 1.07 to 8.70).

138 CI: 1.48-4.55, P = .001), and complaints of dry mouth (OR: 4.58, 95% CI: 1.54-13.63, P = .006).

139 Dry mouth, oral candidiasis, and recurrent aphthous ulce

140 Dry mouth, oral candidiasis, and recurrent aphthous ulce

141 ding (P <0.001), pain on chewing (P <0.001), dry mouth (P <0.001), and oral burning sensations (P <0.

142 global assessment of dry eyes (P = 0.0453), dry mouth (P = 0.0004), and increased salivary flow (P =

143 , logistic dose-response curve) but not with dry mouth (P = 0.63), altered taste (P = 0.27), or saliv

144 tolvaptan were pollakiuria, thirst, fatigue, dry mouth, polydipsia, and polyuria.

145 Cannabis user complaints of dry mouth prompted a study that showed that basal saliva

146 a was assessed based on "yes" responses to a dry-mouth questionnaire.

147 difference between "dry mouth" and "without dry mouth" regarding identification of odors or tastes,

148 on, thus offering a mechanism underlying the dry mouth reported by cannabis users.

149 adverse events were nausea, somnolence, and dry mouth (reported in 0.4 to 4.1%); these events were m

150 Xerostomia is defined as dry mouth resulting from a change in the amount or compo

151 up was associated with a higher incidence of dry mouth (RR=13.0, NNH=5) and sedation (RR=4.59, NNH=5)

152 a, conditions or medications associated with dry mouth, salivary gland enlargement or pregnancy were

153 The subjective symptomatic dry mouth score and the number of mucosal breaks and ulc

154 Dry mouth scores were higher in RT patients over time (P

155 The management of dry mouth should also be recommended for celiac disease

156 were clinically significant improvements in dry-mouth-specific and global quality of life scores.

157 domains: subjective or objective measures of dry mouth, subjective or objective measures of dry eyes,

158 esulting in salivary gland hypofunction with dry mouth symptom.

159 a for treatment of salivary hypofunction and dry mouth symptoms in primary Sjogren's syndrome patient

160 -sectional studies, the global prevalence of dry mouth symptoms was 23% (95% CI, 18% to 28%), placing

161 A total of 289 patients with dry mouth symptoms were evaluated.

162 analog scale questionnaires for dry eye and dry mouth symptoms, lissamine green ocular dye staining

163 Apart from changes over the trial in dry mouth symptoms, no significant differences were note

164 ffer from a devastating side effect known as dry-mouth syndrome, which results from the irreversible

165 s leads to the patient-reported sensation of dry mouth, termed xerostomia, which significantly reduce

166 formulations as a novel topical platform for dry mouth therapy.

167 r purified mucins for saliva substitutes and dry mouth therapy.

168 related adverse reactions primarily included dry mouth, thirst, bradycardia and hypertension.

169 ven [13%] of 55 in the standard IMRT group), dry mouth (three [5%] vs eight [15%]), and dysphagia (th

170 nt includes over-the-counter sialagogues for dry mouth, topical antifungals for oral candidiasis, and

171 nzapine cotherapy group included somnolence, dry mouth, weight gain, increased appetite, tremor, and

172 ache, constipation, dizziness, vomiting, and dry mouth were also more frequent in the naltrexone plus

173 d to chewing, being understood, tasting, and dry mouth were placed in the top three by less than 10%

174 Risks of increased pocket depth and dry mouth were significantly greater in quintile 5 (high

175 Deterioration of dentition and dry mouth were significantly greater in quintile 5 of pe

176 far-reaching consequences, as observed with dry mouth, which is associated with increased orodental

177 veloping effective treatment of irreversible dry mouth, which is common after radiotherapy for head a

178 Complaints of a dry mouth (xerostomia) and sialoadenitis are frequent si

179 eck cancer patients that suffer from chronic dry mouth (xerostomia) due to salivary gland injury from

180 ggest that such an effect could underlie the dry mouth (xerostomia) that occurs as an unexplained sid

181 th dry eyes (keratoconjunctivitis sicca) and dry mouth (xerostomia).

182 nses designed to treat breath malodor (ZnA), dry mouth (ZnB), and gingivitis (ZnC).